Healthcare - Biotechnology - NASDAQ - US
$ 8.19
-3.87 %
$ 526 M
Market Cap
-19.98
P/E
INCOME STATEMENT
0
REVENUE
-23.3 M
OPERATING INCOME
-27 M
NET INCOME
EFFICIENCY
Earnings Waterfall
Corvus Pharmaceuticals, Inc.
| Revenue | 0 |
| Cost Of Revenue | 151 K |
| Gross Profit | -151 K |
| Operating Expenses | 23.4 M |
| Operating Income | -23.3 M |
| Other Expenses | 3.7 M |
| Net Income | -27 M |
Income Statement
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | Dec-2015 | Dec-2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GROSS PROFIT | ||||||||||
| Cost Of Revenue | 0.2 | 0.4 | 0.5 | 0.6 | 0.7 | 0.8 | 0.8 | 0.6 | 0.1 | 0 |
| Gross Profit | (0.2) | (0.4) | (0.5) | (0.6) | (0.7) | (0.8) | (0.8) | (0.6) | (0.1) | 0 |
| OPERATING INCOME | ||||||||||
| Operating Expenses | 23.4 | 32.6 | 38.6 | 43.8 | 48.9 | 49.2 | 56.5 | 37.0 | 13.8 | 0.2 |
| Selling, General and Administrative Expenses | 6.7 | 8.1 | 9.5 | 11.9 | 10.9 | 10.6 | 10.2 | 7.6 | 2.4 | 0.1 |
| Research and Development Expenses | 16.5 | 24.5 | 29.1 | 31.8 | 38.0 | 38.6 | 46.3 | 29.4 | 11.4 | 41.5 K |
| Operating Income | (23.3) | (32.6) | (38.6) | (43.8) | (48.9) | (49.2) | (56.5) | (37.0) | (13.8) | (0.2) |
| PRE-TAX INCOME | ||||||||||
| Interest Income Expense | 1.6 | 0.7 | 15 K | 0.5 | 2.2 | 2.3 | 0 | 0.6 | 0 | 0 |
| Total Other Income | (3.7) | (8.7) | (4.6) | 37.8 | 2.2 | 2.3 | 0.9 | 0.6 | (17.6) | 0 |
| Pre-Tax Income | (27.0) | (41.3) | (43.2) | (6.0) | (46.7) | (46.9) | (55.7) | (36.4) | (31.3) | (0.2) |
| NET INCOME | ||||||||||
| Tax Provision | 0 | 8.7 | (5.0) | (1.2) | (2.9) | 2.3 | (0.8) | (0.6) | 35 K | 0 |
| Net Income | (27.0) | (50.0) | (38.2) | (4.8) | (43.7) | (46.9) | (55.7) | (36.4) | (31.3) | (0.2) |
| EPS | 0.56 | 1.08 | 0.91 | 0.16 | 1.49 | 1.71 | 2.72 | 2.36 | 1.54 | 1.03 |